Monday’s trading has closed, but SIGA is being traded in the after-hours session. After-Hours quote »
Data as of 3:59pm ET
| +0.01 / +0.38%|
SIGA Technologies, Inc. operates as a company specializing in the development and commercialization of solutions for serious unmet medical needs and bio threats. The company specializes in developing therapeutic solutions for some of the most lethal pathogens, which include smallpox, Ebola, dengue, Lassa fever and other dangerous viruses. Its product Arestvyr also known as ST-246, is an orally administered antiviral drug that targets orthopoxviruses. SIGA Technologies was founded on December 28, 1995 and is headquartered in New York, NY.
|Eric A. Rose||Chairman & Chief Executive Officer|
|Daniel J. Luckshire||Chief Financial Officer, Secretary & Executive VP|
|Dennis E. Hruby||Chief Scientific Officer & Vice President|
|William J. Haynes||Executive Vice President & General Counsel|